# Galapagos NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/galapagos

- Industry: Biotechnology
- Headquarters: Mechelen, Belgium
- Website: www.glpg.com
- Total disclosed funding: $19M
- Latest round: Series A (Mar 5, 2002)
- Investors on record: 5

## About

Galapagos NV is a biotechnology company focused on developing and commercializing innovative therapies aimed at improving patient outcomes in chronic autoimmune diseases and malignancies.Founded in 1999 in Mechelen, Belgium, Galapagos NV focuses on biotechnology solutions. The company went public in May 2005, raising EUR 22.4 mn. Its most recent funding round was a Private Placement in 2006, raising EUR 1.28 mn, bringing the total raised to EUR 1.28 mn. Alessandro Pigoni is the founder, and Paul Stoffels serves as the CEO.Galapagos NV specializes in developing innovative biotechnology solutions, including small molecule therapies like the TYK2 inhibitor GLPG3667, which is in Phase 2 trials for systemic lupus erythematosus and other autoimmune conditions. The company also advances its cell therapy platforms, offering scalable and decentralized treatment solutions. Geographically, Galapagos targets Europe and the United States, collaborating with partners to enhance patient access to its therapies.In 2024, Galapagos NV reported a revenue of EUR 328,374,702.2 and an EBITDA of EUR 81,958,111. The company generates revenue through partnerships and licensing agreements with pharmaceutical firms, focusing on B2B transactions to develop and distribute its products.Galapagos NV aims to launch new therapies including the TYK2 inhibitor GLPG3667 and expand its market reach into Europe and the United States by leveraging recent funding through strategic partnerships. The company is also poised for growth following its initial public offering in 2005 and is focused on developing its innovative biotechnology solutions to meet the needs of patients with chronic autoimmune diseases.

## Funding rounds

- Series A, Mar 5, 2002, $19M — Abingworth, Apax Partners, Burrill & Company, Janssen Vaccines & Prevention B.V., NIBC Holding N.V.

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A
- Apax Partners (https://capitalatlas.ai/funds/apax-partners) — Series A
- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series A
- Janssen Vaccines & Prevention B.V. — Series A
- NIBC Holding N.V. — Series A